These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7797782)

  • 1. A one-year perspective on MedWatch: the Food and Drug Administration's new medical products reporting program.
    Gruchalla RS
    J Allergy Clin Immunol; 1995 Jun; 95(6):1153-7. PubMed ID: 7797782
    [No Abstract]   [Full Text] [Related]  

  • 2. MEDWatch: the new FDA medical products reporting program.
    Kessler DA
    Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
    [No Abstract]   [Full Text] [Related]  

  • 3. MedWatch: the new medical products reporting program.
    Couig MP; Merkatz RB
    Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
    [No Abstract]   [Full Text] [Related]  

  • 4. The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
    Madabushi R; Benjamin JM; Grewal R; Pacanowski MA; Strauss DG; Wang Y; Zhu H; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):74-78. PubMed ID: 31081932
    [No Abstract]   [Full Text] [Related]  

  • 5. MedWatch: the FDA medical products reporting program.
    Rheinstein PH
    Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
    [No Abstract]   [Full Text] [Related]  

  • 6. MedWatch: FDA's Medical Products Reporting Program.
    Goldman SA; Kennedy DL
    Postgrad Med; 1998 Mar; 103(3):13-6. PubMed ID: 9519028
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food and Drug Administration update. The MedWatch program.
    White GG; Love L
    J Toxicol Clin Toxicol; 1998; 36(1-2):145-9. PubMed ID: 9541064
    [No Abstract]   [Full Text] [Related]  

  • 9. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA; Stein CM
    N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
    [No Abstract]   [Full Text] [Related]  

  • 10. Federal Drug Administration authority and the emergency nurse: implications for patient safety.
    Hackenschmidt A
    J Emerg Nurs; 2006 Oct; 32(5):449-50. PubMed ID: 16997042
    [No Abstract]   [Full Text] [Related]  

  • 11. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MedWatch program.
    White GG
    Int J Trauma Nurs; 1998; 4(3):100-3. PubMed ID: 9855977
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmarketing surveillance: beyond MEDWatch.
    Faich GA
    JAMA; 1993 Nov; 270(18):2180. PubMed ID: 8411596
    [No Abstract]   [Full Text] [Related]  

  • 18. The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):243-246. PubMed ID: 29871507
    [No Abstract]   [Full Text] [Related]  

  • 19. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
    Kessler DA
    J Am Podiatr Med Assoc; 1994 Jan; 84(1):35-8. PubMed ID: 8295131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.